Catarig, Andrei-Mircea

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 412

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Lingvay, I., Catarig, A.-M., Frias, J. P., Kumar, H., Lausvig, N. L., le Roux, C. W., Thielke, D., Viljoen, A., & McCrimmon, R. J. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 298

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

McCrimmon, R. J., Catarig, A.-M., Frias, J. P., Lausvig, N. L., le Roux, C. W., Thielke, D., & Lingvay, I. (2020) · Diabetologia

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 184

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

Bonaca, M. P., Catarig, A.-M., Houlind, K., Ludvik, B., Nordanstig, J., Ramesh, C. K., Rasouli, N., Sourij, H., Videmark, A., & Verma, S. (2025) · The Lancet

Peripheral Artery Disease ManagementDiabetes Treatment and Management

Cited by 176

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study

Rajamand Ekberg, N., Bodholdt, U., Catarig, A.-M., Catrina, S.-B., Grau, K., Holmberg, C. N., Klanger, B., & Knudsen, S. T. (2021) · Primary Care Diabetes

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 63

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups

Yale, J.-F., Bodholdt, U., Catarig, A.-M., Catrina, S., Clark, A., Ekberg, N. R., Erhan, U., Holmes, P., Knudsen, S. T., Liutkus, J., et al. (2022) · BMJ Open Diabetes Research & Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 50

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study

Rudofsky, G., Catarig, A.-M., Favre, L., Grau, K., Häfliger, S., Thomann, R., & Schultes, B. (2021) · Diabetes Research and Clinical Practice

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 46

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study

Holmes, P., Bell, H. E., Bozkurt, K., Catarig, A.-M., Clark, A., Machell, A., & Sathyapalan, T. (2021) · Diabetes Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 42

Adherence to glucagon‐like peptide ‐1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study

Lassen, M. C. H., Johansen, N. D., Modin, D., Catarig, A., Vistisen, B. K., Amadid, H., Zimmermann, E., Gislason, G., & Biering‐Sørensen, T. (2024) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementMedication Adherence and Compliance

Cited by 40

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany

Menzen, M., Berentzen, T. L., Catarig, A.-M., Pieperhoff, S., Simon, J., & Jacob, S. (2023) · Experimental and Clinical Endocrinology & Diabetes

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 29

Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study

Wolffenbuttel, B. H. R., Brugts, M. P., Catarig, A.-M., Clark, A., Kok, M., Lieverse, A. G., & van Soest, J. (2023) · Advances in Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 26

Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis

Rudofsky, G., Menzen, M., Potier, L., Catarig, A.-M., Clark, A., Priyadarshini, P., & Abreu, C. (2025) · Advances in Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 3